Aerovate Launches Clinical Trial of AV-101 in PAH

Aerovate Launches Clinical Trial of AV-101 in PAH

314495

Aerovate Launches Clinical Trial of AV-101 in PAH

Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib, in people with pulmonary arterial hypertension (PAH). “We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101. Starting enrollment represents an important milestone for Aerovate Therapeutics and advances our goal of improving the lives of patients suffering from rare cardiovascular diseases,” Tim Noyes, Aerovate’s CEO, said in a press release. The trial, called IMPAHCT…

You must be logged in to read/download the full post.